Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG2102 NACLESS trial
jRCTs031220446Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin and ifosfamide in soft tissue sarcoma (STS) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Overall survival. Started Nov 2022; status: recruiting.
02
Drugs
doxorubicinifosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on jRCTs031220446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220446.